The synthetic cathinone α-pyrrolidinovalerophenone (α-PVP): pharmacokinetic and pharmacodynamic clinical and forensic aspects

References

• Aarde SM, Vandewater S, Creehan K, Taffe MA. 2015. Alpha-pyrrolidinovalerophenone (alpha-PVP): Self-administration and acute drug challenges in rats. Drug Alcohol Depend. 146:e202.
   Google Scholar
• Adamowicz P, Gieron J, Gil D, Lechowicz W, Skulska A, Tokarczyk B. 2016a. The prevalence of new psychoactive substances in biological material – a three-year review of casework in Poland. Drug Test Anal. 8:63–70.
   PubMed Web of Science ®Google Scholar
• Adamowicz P, Gieroń J, Gil D, Lechowicz W, Skulska A, Tokarczyk B, Zuba D. 2016b. Blood concentrations of α-pyrrolidinovalerophenone (α-PVP) determined in 66 forensic samples. Forensic Toxicol. 34:227–234.
   Web of Science ®Google Scholar
• Adas F, Berthou F, Salaun JP, Dreano Y, Amet Y. 1999. Interspecies variations in fatty acid hydroxylations involving cytochromes P450 2E1 and 4A. Toxicol Lett. 110:43–55.
   PubMed Web of Science ®Google Scholar
• Adas F, Salaun JP, Berthou F, Picart D, Simon B, Amet Y. 1999. Requirement for omega and (omega;-1)-hydroxylations of fatty acids by human cytochromes P450 2E1 and 4A11. J Lipid Res. 40:1990–1997.
   PubMed Web of Science ®Google Scholar
• Banks ML, Worst TJ, Rusyniak DE, Sprague JE. 2014. Synthetic cathinones (“Bath Salts”). J Emerg Med. 46:632–642.
   PubMed Web of Science ®Google Scholar
• Barbosa J, Faria J, Queiros O, Moreira R, Carvalho F, Dinis-Oliveira RJ. 2016. Comparative metabolism of tramadol and tapentadol: a toxicological perspective. Drug Metab Rev. 48:577–592.
   PubMed Web of Science ®Google Scholar
• Baumann MH, Bukhari MO, Lehner KR, Anizan S, Rice KC, Concheiro M, Huestis MA. 2017. Neuropharmacology of 3,4-methylenedioxypyrovalerone (MDPV), its metabolites, and related analogs. Curr Top Behav Neurosci. 32:93–117.
   PubMedGoogle Scholar
• Baumann MH, Partilla JS, Lehner KR. 2013. Psychoactive “bath salts”: not so soothing. Eur J Pharmacol. 698:1–5.
   PubMed Web of Science ®Google Scholar
• Beck O, Backberg M, Signell P, Helander A. 2018. Intoxications in the STRIDA project involving a panorama of psychostimulant pyrovalerone derivatives, MDPV copycats. Clin Toxicol (Phila). 56:256–263.
   PubMed Web of Science ®Google Scholar
• Beck O, Franzen L, Backberg M, Signell P, Helander A. 2016. Toxicity evaluation of α-pyrrolidinovalerophenone (α-PVP): results from intoxication cases within the STRIDA project. Clin Toxicol (Phila). 54:568–575.
   PubMed Web of Science ®Google Scholar
• Boehringer Ingelheim GmbH. 1967 Apr 18. α-Pyrrolidino ketones, in: United States Patent Office, 3314970 A.
   Google Scholar
• Byrska B, Stanaszek R, Zuba D. 2017. Alpha-PVP as an active component of herbal highs in Poland between 2013 and 2015. Drug Test Anal. 9:1267–1274.
   PubMed Web of Science ®Google Scholar
• Cashman JR. 2000. Human flavin-containing monooxygenase: substrate specificity and role in drug metabolism. Curr Drug Metab. 1:181–191.
   PubMed Web of Science ®Google Scholar
• Chapy H, Smirnova M, Andre P, Schlatter J, Chiadmi F, Couraud PO, Scherrmann JM, Decleves X, Cisternino S. 2014. Carrier-mediated cocaine transport at the blood-brain barrier as a putative mechanism in addiction liability. Int J Neuropsychopharmacol. 18:pyu001.
   PubMed Web of Science ®Google Scholar
• Cherry SV, Rodriguez YF. 2017. Synthetic stimulant reaching epidemic proportions: flakka-induced ST-elevation myocardial infarction with intracardiac thrombi. J Cardiothorac Vasc Anesth. 31:e13–e14.
   PubMedGoogle Scholar
• Coppola M, Mondola R. 2012. Synthetic cathinones: chemistry, pharmacology and toxicology of a new class of designer drugs of abuse marketed as “bath salts” or “plant food”. Toxicol Lett. 211:144–149.
   PubMed Web of Science ®Google Scholar
• Dinis-Oliveira RJ. 2016a. Metabolomics of Δ9-tetrahydrocannabinol: implications in toxicity. Drug Metab Rev. 48:80–87.
   PubMed Web of Science ®Google Scholar
• Dinis-Oliveira RJ. 2016b. Metabolomics of methadone: clinical and forensic toxicological implications and variability of dose response. Drug Metab Rev. 48:568–576.
   PubMed Web of Science ®Google Scholar
• Dinis-Oliveira RJ. 2017a. Metabolic profile of flunitrazepam: clinical and forensic toxicological aspects. Drug Metab Lett. 11:14–20.
   PubMedGoogle Scholar
• Dinis-Oliveira RJ. 2017b. Metabolic profile of oxazepam and related benzodiazepines: clinical and forensic aspects. Drug Metab Rev. 49:451–463.
   PubMed Web of Science ®Google Scholar
• Dinis-Oliveira RJ. 2017c. Metabolism of psilocybin and psilocin: clinical and forensic toxicological relevance. Drug Metab Rev. 49:84–91.
   PubMed Web of Science ®Google Scholar
• Dumestre-Toulet V, Brault S, Labadie M, Penouil-Pucheu F. 2017. Madness with five dollars: Two new cases of non-lethal poisoning flakka (α-PVP). Toxicologie Analytique Et Clinique. 29:111–116.
   Web of Science ®Google Scholar
• Eiden C, Mathieu O, Cathala P, Debruyne D, Baccino E, Petit P, Peyriere H. 2013. Toxicity and death following recreational use of 2-pyrrolidino valerophenone. Clin Toxicol (Phila). 51:899–903.
   PubMed Web of Science ®Google Scholar
• EMCDDA. 2016. Report on the risk assessment of 1-phenyl-2-(pyrrolidin-1-yl)pentan-1-one (α-pyrrolidinovalerophenone, α-PVP) in the framework of the Council Decision on new psychoactive substances, Risk Assessments, Publications Office of the European Union, Luxembourg; [accessed 2018 Feb 15]. http://www.emcdda.europa.eu/system/files/publications/2934/TDAK16-001ENN.pdf.
   Google Scholar
• EMCDDA. 2017. European Drug Report 2017: Trends and Developments, Publications Office of the European Union, Luxembourg; [accessed 2018 Feb 15]. http://www.emcdda.europa.eu/system/files/publications/4541/TDAT17001ENN.pdf.
   Google Scholar
• Eshleman AJ, Wolfrum KM, Reed JF, Kim SO, Swanson T, Johnson RA, Janowsky A. 2017. Structure-activity relationships of substituted cathinones, with transporter binding, uptake, and release. J Pharmacol Exp Ther. 360:33–47.
   PubMed Web of Science ®Google Scholar
• Fernandes C, Tiritan ME, Pinto M. 2013. Small molecules as chromatographic tools for HPLC enantiomeric resolution: pirkle-type chiral stationary phases evolution. Chromatographia. 76:871–897.
   Web of Science ®Google Scholar
• Fernandez Alonso C, Quintela Jorge O, Santiago Saez AS. 2016. [Identification of the drug of abuse flakka (alpha-PVP) as suspicion of chemical submission in the Emergency Department of a tertiary hospital]. Medicina Clinica. 147:227–228.
   PubMed Web of Science ®Google Scholar
• Fratantonio J, Andrade L, Febo M. 2015. Designer drugs: a synthetic catastrophe. J Reward Defic Syndr. 1:82–86.
   PubMedGoogle Scholar
• Gannon BM, Rice KC, Collins GT. 2017. Reinforcing effects of abused 'bath salts' constituents 3,4-methylenedioxypyrovalerone and α-pyrrolidinopentiophenone and their enantiomers. Behav Pharmacol. 28:578–581.
   PubMed Web of Science ®Google Scholar
• Gannon BM, Williamson A, Suzuki M, Rice KC, Fantegrossi WE. 2016. Stereoselective effects of abused “bath salt” constituent 3,4-methylenedioxypyrovalerone in mice: drug discrimination, locomotor activity, and thermoregulation. J Pharmacol Exp Ther. 356:615–623.
   PubMed Web of Science ®Google Scholar
• Gatch MB, Dolan SB, Forster MJ. 2015. Comparative behavioral pharmacology of three pyrrolidine-containing synthetic cathinone derivatives. J Pharmacol Exp Ther. 354:103–110.
   PubMed Web of Science ®Google Scholar
• Giannotti G, Canazza I, Caffino L, Bilel S, Ossato A, Fumagalli F, Marti M. 2017. The cathinones MDPV and α-PVP elicit different behavioral and molecular effects following acute exposure. Neurotox Res. 32:594–602.
   PubMed Web of Science ®Google Scholar
• Giese C, Igoe D, Gibbons Z, Hurley C, Stokes S, McNamara S, Ennis O, O'Donnell K, Keenan E, De Gascun C, et al. 2015. Injection of new psychoactive substance snow blow associated with recently acquired HIV infections among homeless people who inject drugs in Dublin, Ireland, 2015. Euro Surveill. 20. https://doi.org/10.2807/1560-7917.ES.2015.20.40.30036.
   PubMedGoogle Scholar
• Glennon RA, Young R. 2016. Neurobiology of 3,4-methylenedioxypyrovalerone (MDPV) and alpha-pyrrolidinovalerophenone (alpha-PVP). Brain Res Bull. 126:111–126.
   PubMed Web of Science ®Google Scholar
• Glicksberg L, Bryand K, Kerrigan S. 2016. Identification and quantification of synthetic cathinones in blood and urine using liquid chromatography-quadrupole/time of flight (LC-Q/TOF) mass spectrometry. J Chromatogr B. 1035:91–103.
   PubMed Web of Science ®Google Scholar
• Grapp M, Sauer C, Vidal C, Muller D. 2016. GC-MS analysis of the designer drug alpha-pyrrolidinovalerophenone and its metabolites in urine and blood in an acute poisoning case. Forensic Sci Int. 259:e14–e19.
   PubMed Web of Science ®Google Scholar
• Gregg RA, Hicks C, Nayak SU, Tallarida CS, Nucero P, Smith GR, Reitz AB, Rawls SM. 2016. Synthetic cathinone MDPV downregulates glutamate transporter subtype I (GLT-1) and produces rewarding and locomotor-activating effects that are reduced by a GLT-1 activator. Neuropharmacology. 108:111–119.
   PubMed Web of Science ®Google Scholar
• Heikman P, Sundstrom M, Pelander A, Ojanpera I. 2016. New psychoactive substances as part of polydrug abuse within opioid maintenance treatment revealed by comprehensive high-resolution mass spectrometric urine drug screening. Hum Psychopharmacol. 31:44–52.
   PubMed Web of Science ®Google Scholar
• Holsztynska EJ, Domino EF. 1985. Biotransformation of phencyclidine. Drug Metab Rev. 16:285–320.
   PubMed Web of Science ®Google Scholar
• Huskinson SL, Naylor JE, Townsend EA, Rowlett JK, Blough BE, Freeman KB. 2017. Self-administration and behavioral economics of second-generation synthetic cathinones in male rats. Psychopharmacology (Berl). 234:589–598.
   PubMed Web of Science ®Google Scholar
• Johnson PS, Johnson MW. 2014. Investigation of “Bath Salts” Use Patterns Within an Online Sample of Users in the United States. J Psychoactive Drugs.46:369–378.
   PubMed Web of Science ®Google Scholar
• Kaizaki A, Tanaka S, Numazawa S. 2014. New recreational drug 1-phenyl-2-(1-pyrrolidinyl)-1-pentanone (alpha-PVP) activates central nervous system via dopaminergic neuron. J Toxicol Sci. 39:1–6.
   PubMed Web of Science ®Google Scholar
• Karila L, Lafaye G, Scocard A, Cottencin O, Benyamina A. 2017. MDPV and α-PVP use in humans: The twisted sisters. Neuropharmacology. https://doi.org/10.1016/j.neuropharm.2017.10.007.
   Google Scholar
• Kesha K, Boggs CL, Ripple MG, Allan CH, Levine B, Jufer-Phipps R, Doyon S, Chi P, Fowler DR. 2013. Methylenedioxypyrovalerone (“bath salts”), related death: case report and review of the literature. J Forensic Sci. 58:1654–1659.
   PubMed Web of Science ®Google Scholar
• Kolanos R, Partilla JS, Baumann MH, Hutsell BA, Banks ML, Negus SS, Glennon RA. 2015a. Stereoselective actions of methylenedioxypyrovalerone (MDPV) to inhibit dopamine and norepinephrine transporters and facilitate intracranial self-stimulation in rats. ACS Chem Neurosci. 6:771–777.
   PubMed Web of Science ®Google Scholar
• Kolanos R, Sakloth F, Jain AD, Partilla JS, Baumann MH, Glennon RA. 2015b. Structural modification of the designer stimulant alpha-pyrrolidinovalerophenone (alpha-PVP) influences potency at dopamine transporters. ACS Chem Neurosci. 6:1726–1731.
   PubMed Web of Science ®Google Scholar
• Lassiter PS, Buser TJ. 2017. Annual review of addictions and offender counseling, volume III: Best Practices. Eugene: Resource Publications.
   Google Scholar
• Levine M, Levitan R, Skolnik A. 2013. Compartment syndrome after “bath salts” use: a case series. Ann Emerg Med. 61:480–483.
   PubMed Web of Science ®Google Scholar
• Marinetti LJ, Antonides HM. 2013. Analysis of synthetic cathinones commonly found in bath salts in human performance and postmortem toxicology: method development, drug distribution and interpretation of results. J Anal Toxicol. 37:135–146.
   PubMed Web of Science ®Google Scholar
• Marusich JA, Antonazzo KR, Wiley JL, Blough BE, Partilla JS, Baumann MH. 2014. Pharmacology of novel synthetic stimulants structurally related to the “bath salts” constituent 3,4-methylenedioxypyrovalerone (MDPV). Neuropharmacology. 87:206–213.
   PubMed Web of Science ®Google Scholar
• Marusich JA, Lefever TW, Blough BE, Thomas BF, Wiley JL. 2016. Pharmacological effects of methamphetamine and alpha-PVP vapor and injection. Neurotoxicology. 55:83–91.
   PubMed Web of Science ®Google Scholar
• Matsuta S, Shima N, Kamata H, Kakehashi H, Nakano S, Sasaki K, Kamata T, Nishioka H, Miki A, Katagi M, et al. 2015. Metabolism of the designer drug α-pyrrolidinobutiophenone (α-PBP) in humans: identification and quantification of the phase I metabolites in urine. Forensic Sci Int. 249:181–188.
   PubMed Web of Science ®Google Scholar
• Milhorn HT. 2017. Substance use disorders: a guide for the primary care provider. Cham, Switzerland: Springer International Publishing.
   Google Scholar
• Miller B, Kim J, Concheiro M. 2017. Stability of synthetic cathinones in oral fluid samples. Forensic Sci Int. 274:13–21.
   PubMed Web of Science ®Google Scholar
• Nagai H, Saka K, Nakajima M, Maeda H, Kuroda R, Igarashi A, Tsujimura-Ito T, Nara A, Komori M, Yoshida K. 2014. Sudden death after sustained restraint following self-administration of the designer drug α-pyrrolidinovalerophenone. Int J Cardiol. 172:263–265.
   PubMed Web of Science ®Google Scholar
• Namera A, Konuma K, Kawamura M, Saito T, Nakamoto A, Yahata M, Ohta S, Miyazaki S, Shiraishi H, Nagao M. 2014. Time-course profile of urinary excretion of intravenously administered α-pyrrolidinovalerophenone and α-pyrrolidinobutiophenone in a human. Forensic Toxicol. 32:68–74.
   Web of Science ®Google Scholar
• Namera A, Konuma K, Saito T, Ota S, Oikawa H, Miyazaki S, Urabe S, Shiraishi H, Nagao M. 2013. Simple segmental hair analysis for alpha-pyrrolidinophenone-type designer drugs by MonoSpin extraction for evaluation of abuse history. J Chromatogr B. 942-943:15–20.
   PubMed Web of Science ®Google Scholar
• Naylor JE, Freeman KB, Blough BE, Woolverton WL, Huskinson SL. 2015. Discriminative-stimulus effects of second generation synthetic cathinones in methamphetamine-trained rats. Drug Alcohol Depend. 149:280–284.
   PubMed Web of Science ®Google Scholar
• Negreira N, Erratico C, Kosjek T, van Nuijs AL, Heath E, Neels H, Covaci A. 2015. In vitro Phase I and Phase II metabolism of α-pyrrolidinovalerophenone (α-PVP), methylenedioxypyrovalerone (MDPV) and methedrone by human liver microsomes and human liver cytosol. Anal Bioanal Chem. 407:5803–5816.
   PubMed Web of Science ®Google Scholar
• Nelson G, Shah S, Cury J. 2017. Does procalcitonin “Get High” on flakka? a case of extreme procalcitonin elevation due to psychostimulant abuse. Chest. 152:A382.
   Web of Science ®Google Scholar
• Nelson KH, Hempel BJ, Clasen MM, Rice KC, Riley AL. 2017. Conditioned taste avoidance, conditioned place preference and hyperthermia induced by the second generation 'bath salt' alpha-pyrrolidinopentiophenone (alpha-PVP). Pharmacol Biochem Behav. 156:48–55.
   PubMed Web of Science ®Google Scholar
• Nguyen JD, Bremer PT, Ducime A, Creehan KM, Kisby BR, Taffe MA, Janda KD. 2017. Active vaccination attenuates the psychostimulant effects of α-PVP and MDPV in rats. Neuropharmacology. 116:1–8.
   PubMed Web of Science ®Google Scholar
• Novellas J, Lopez-Arnau R, Carbo ML, Pubill D, Camarasa J, Escubedo E. 2015. Concentrations of MDPV in rat striatum correlate with the psychostimulant effect. J Psychopharmacol (Oxford). 29:1209–1218.
   PubMed Web of Science ®Google Scholar
• Patel N, Ford L, Jones R, Bradberry SM, Vale JA. 2017. Poisoning to α-pyrrolidinovalerophenone (α-PVP), a synthetic cathinone. Clin Toxicol (Phila). 55:159–160.
   PubMed Web of Science ®Google Scholar
• Potocka-Banas B, Janus T, Majdanik S, Banas T, Dembinska T, Borowiak K. 2017. Fatal intoxication with α-PVP, a synthetic cathinone derivative. J Forensic Sci. 62:553–556.
   PubMed Web of Science ®Google Scholar
• Prosser JM, Nelson LS. 2012. The toxicology of bath salts: a review of synthetic cathinones. J Med Toxicol. 8:33–42.
   PubMedGoogle Scholar
• Quesada L, Gomila I, Yates C, Barcelo C, Puiguriguer J, Barcelo B. 2016. Elimination half-life of alpha-pyrrolidinovalerophenone in an acute non-fatal intoxication. Clin Toxicol (Phila). 54:531–532.
   PubMed Web of Science ®Google Scholar
• Rickli A, Hoener MC, Liechti ME. 2015. Monoamine transporter and receptor interaction profiles of novel psychoactive substances: para-halogenated amphetamines and pyrovalerone cathinones. Eur Neuropsychopharmacol. 25:365–376.
   PubMed Web of Science ®Google Scholar
• Rojek S, Kula K, Maciow-Glab M, Klys M. 2016. New psychoactive substance α-PVP in a traffic accident case. Forensic Toxicol. 34:403–410.
   PubMed Web of Science ®Google Scholar
• Salomone A, Palamar JJ, Gerace E, Di Corcia D, Vincenti M. 2017. Hair testing for drugs of abuse and new psychoactive substances in a high-risk population. J Anal Toxicol. 41:376–381.
   PubMed Web of Science ®Google Scholar
• Sauer C, Peters FT, Haas C, Meyer MR, Fritschi G, Maurer HH. 2009. New designer drug alpha-pyrrolidinovalerophenone (PVP): studies on its metabolism and toxicological detection in rat urine using gas chromatographic/mass spectrometric techniques. J Mass Spectrom. 44:952–964.
   PubMed Web of Science ®Google Scholar
• Sewalia K, Watterson LR, Hryciw A, Belloc A, Ortiz JB, Olive MF. 2017. Neurocognitive dysfunction following repeated binge-like self-administration of the synthetic cathinone 3,4-methylenedioxypyrovalerone (MDPV). Neuropharmacology. https://doi.org/10.1016/j.neuropharm.2017.11.034.
   PubMed Web of Science ®Google Scholar
• Shima N, Katagi M, Kamata H, Matsuta S, Sasaki K, Kamata T, Nishioka H, Miki A, Tatsuno M, Zaitsu K, et al. 2014. Metabolism of the newly encountered designer drug α-pyrrolidinovalerophenone in humans: identification and quantitation of urinary metabolites. Forensic Toxicol. 32:59–67.
   Web of Science ®Google Scholar
• Shin H, Park J. 1994. Identification of the new metabolites of pyrovalerone by various derivatization methods in the rat urine. Korean Biochemical J. 27:357.
   Google Scholar
• Silva B, Fernandes C, Tiritan ME, Pinto MM, Valente MJ, Carvalho M, de Pinho PG, Remiao F. 2016. Chiral enantioresolution of cathinone derivatives present in “legal highs”, and enantioselectivity evaluation on cytotoxicity of 3,4-methylenedioxypyrovalerone (MDPV). Forensic Toxicol. 34:372–385.
   PubMed Web of Science ®Google Scholar
• Simmler LD, Buser TA, Donzelli M, Schramm Y, Dieu LH, Huwyler J, Chaboz S, Hoener MC, Liechti ME. 2013. Pharmacological characterization of designer cathinones in vitro. Br J Pharmacol. 168:458–470.
   PubMed Web of Science ®Google Scholar
• Smith DA, Negus SS, Poklis JL, Blough BE, Banks ML. 2017. Cocaine-like discriminative stimulus effects of alpha-pyrrolidinovalerophenone, methcathinone and their 3,4-methylenedioxy or 4-methyl analogs in rhesus monkeys. Addict Biol. 22:1169–1178.
   PubMed Web of Science ®Google Scholar
• Springer D, Fritschi G, Maurer HH. 2003a. Metabolism and toxicological detection of the new designer drug 3',4'-methylenedioxy-alpha-pyrrolidinopropiophenone studied in urine using gas chromatography-mass spectrometry. J Chromatogr B. 793:377–388.
   PubMed Web of Science ®Google Scholar
• Springer D, Fritschi G, Maurer HH. 2003b. Metabolism and toxicological detection of the new designer drug 4'-methoxy-alpha-pyrrolidinopropiophenone studied in rat urine using gas chromatography-mass spectrometry. J Chromatogr B. 793:331–342.
   PubMed Web of Science ®Google Scholar
• Springer D, Fritschi G, Maurer HH. 2003c. Metabolism of the new designer drug alpha-pyrrolidinopropiophenone (PPP) and the toxicological detection of PPP and 4'-methyl-alpha-pyrrolidinopropiophenone (MPPP) studied in rat urine using gas chromatography-mass spectrometry. J Chromatogr B. 796:253–266.
   PubMed Web of Science ®Google Scholar
• Springer D, Paul LD, Staack RF, Kraemer T, Maurer HH. 2003. Identification of cytochrome p450 enzymes involved in the metabolism of 4'-methyl-alpha-pyrrolidinopropiophenone, a novel scheduled designer drug, in human liver microsomes. Drug Metab Dispos. 31:979–982.
   PubMed Web of Science ®Google Scholar
• Springer D, Peters FT, Fritschi G, Maurer HH. 2003. New designer drug 4'-methyl-alpha-pyrrolidinohexanophenone: studies on its metabolism and toxicological detection in urine using gas chromatography-mass spectrometry. J Chromatogr B. 789:79–91.
   PubMed Web of Science ®Google Scholar
• Stanciu CN, Penders TM, Gnanasegaram SA, Pirapakaran E, Padda JS, Padda JS. 2017. The Behavioral Profile of methylenedioxypyrovalerone (MDPV) and alpha-pyrrolidinopentiophenone (PVP) – a systematic review. Curr Drug Abuse Rev. https://doi.org/10.2174/1874473710666170321122226.
   PubMedGoogle Scholar
• Sundstrom M, Pelander A, Simojoki K, Ojanpera I. 2016. Patterns of drug abuse among drug users with regular and irregular attendance for treatment as detected by comprehensive UHPLC-HR-TOF-MS. Drug Test Anal. 8:39–45.
   PubMed Web of Science ®Google Scholar
• Tyrkkö E, Pelander A, Ketola RA, Ojanperä I. 2013. In silico and in vitro metabolism studies support identification of designer drugs in human urine by liquid chromatography/quadrupole-time-of-flight mass spectrometry. Anal Bioanal Chem. 405:6697–6709.
   PubMed Web of Science ®Google Scholar
• Umebachi R, Aoki H, Sugita M, Taira T, Wakai S, Saito T, Inokuchi S. 2016. Clinical characteristics of alpha-pyrrolidinovalerophenone (alpha-PVP) poisoning. Clin Toxicol (Phila). 54:563–567.
   PubMed Web of Science ®Google Scholar
• UNODC. 2017a. 2017 Global Synthetic Drugs Assessment; [accessed 2018 Feb 15]. https://www.unodc.org/documents/scientific/Global_Drugs_Assessment_2017.pdf.
   Google Scholar
• UNODC. 2017b. World Drug Report 2017; [accessed 2018 Feb 15]. https://www.unodc.org/wdr2017/index.html.
   Google Scholar
• Uralets V, Rana S, Morgan S, Ross W. 2014. Testing for designer stimulants: metabolic profiles of 16 synthetic cathinones excreted free in human urine. J Anal Toxicol. 38:233–241.
   PubMed Web of Science ®Google Scholar
• Valente MJ, Guedes de Pinho P, de Lourdes Bastos M, Carvalho F, Carvalho M. 2014. Khat and synthetic cathinones: a review. Arch Toxicol. 88:15–45.
   PubMed Web of Science ®Google Scholar
• Valento M, Lebin J. 2017. Emerging drugs of abuse: synthetic cannabinoids, phenylethylamines (2C Drugs), and synthetic cathinones. Clin Pediatr Emerg Med. 18:203–211.
   Web of Science ®Google Scholar
• Vickers S, Polsky SL. 2000. The biotransformation of nitrogen containing xenobiotics to lactams. Curr Drug Metab. 1:357–389.
   PubMed Web of Science ®Google Scholar
• WADA. 2016. Prohibited List. January 2016; [accessed 2018 Feb 15]. https://www.wada-ama.org/sites/default/files/resources/files/wada-2016-prohibited-list-en.pdf.
   Google Scholar
• Wander A. 1963 May 29. α-Pyrrolidino valerophenone. British Patent 927,475.
   Google Scholar
• Watterson LR, Burrows BT, Hernandez RD, Moore KN, Grabenauer M, Marusich JA, Olive MF. 2014. Effects of alpha-pyrrolidinopentiophenone and 4-methyl-N-ethylcathinone, two synthetic cathinones commonly found in second-generation “bath salts,” on intracranial self-stimulation thresholds in rats. Int J Neuropsychopharmacol. 18:pyu014.
   PubMed Web of Science ®Google Scholar
• Watterson LR, Olive MF. 2014. Synthetic cathinones and their rewarding and reinforcing effects in rodents. Adv Neurosci (Hindawi). 2014:209875.
   PubMedGoogle Scholar
• Wille SMR, Richeval C, Nachon-Phanithavong M, Gaulier JM, Di Fazio V, Humbert L, Samyn N, Allorge D. 2017. Prevalence of new psychoactive substances and prescription drugs in the Belgian driving under the influence of drugs population. Drug Test Anal. https://doi.org/10.1002/dta.2232
   PubMed Web of Science ®Google Scholar
• Wood MR, Bernal I, Lalancette RA. 2016. The dangerous new synthetic drug α-PVP as the hydrated chloride salt α-pyrrolidinopentiophenone hydrochloride 0.786-hydrate. Acta Crystallogr C Struct Chem. 72:48–51.
   PubMed Web of Science ®Google Scholar
• Wright TH, Harris C. 2016. Twenty-one cases involving alpha-pyrrolidinovalerophenone (α-PVP). J Anal Toxicol. 40:396–402.
   PubMed Web of Science ®Google Scholar
• Wurita A, Hasegawa K, Minakata K, Gonmori K, Nozawa H, Yamagishi I, Suzuki O, Watanabe K. 2014. Postmortem distribution of α-pyrrolidinobutiophenone in body fluids and solid tissues of a human cadaver. Leg Med (Tokyo). 16:241–246.
   PubMed Web of Science ®Google Scholar
• Zawilska JB, Wojcieszak J. 2017. α-Pyrrolidinophenones: a new wave of designer cathinones. Forensic Toxicol. 35:201–216.
   Web of Science ®Google Scholar
• Zwartsen A, Verboven AHA, van Kleef R, Wijnolts FMJ, Westerink RHS, Hondebrink L. 2017. Measuring inhibition of monoamine reuptake transporters by new psychoactive substances (NPS) in real-time using a high-throughput, fluorescence-based assay. Toxicol in Vitro. 45:60–71.
   PubMed Web of Science ®Google Scholar